Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company

Core Insights - Nxera Pharma has entered into a license agreement with a newly established independent company, NewCo, to advance its G protein-coupled receptor (GPCR)-targeted program [1][2] - Nxera has received an equity stake in NewCo and is entitled to milestone payments and royalties upon successful development and commercialization of the asset [2] - Nxera retains rights to develop and commercialize the asset in Japan and certain Asia-Pacific territories in the future [2] - The partnership with NewCo is aimed at maximizing the value of the Program and enabling it to reach patients [3] - Nxera may participate in a Series A financing round of NewCo alongside major global investment firms [3] - The impact of the agreement on Nxera's consolidated financial results for the fiscal year ending 31 December 2026 is under review [4] Company Overview - Nxera Pharma is a technology-powered biopharma company focused on developing specialty medicines for patients with unmet needs in Japan and globally [6] - The company has established a new-generation commercial business in Japan and is advancing an extensive pipeline through its unique NxWave™ GPCR structure-based drug discovery platform [6] - Nxera operates in key locations including Tokyo, Osaka, London, Cambridge, Basel, and Seoul, and is listed on the Tokyo Stock Exchange under ticker 4565 [6]